CRNX (Crinetics Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 98.19% (As of Dec. 15, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Crinetics Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Crinetics Pharmaceuticals's float shares is 91.06 Mil. Crinetics Pharmaceuticals's total shares outstanding is 92.74 Mil. Crinetics Pharmaceuticals's float percentage of total shares outstanding is 98.19%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Crinetics Pharmaceuticals's Insider Ownership is 1.02%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Crinetics Pharmaceuticals's Institutional Ownership is 98.26%.

Crinetics Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Crinetics Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	91.06	/	92.74
	=	98.19%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crinetics Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crinetics Pharmaceuticals Inc (NAS:CRNX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

6Z4:Germany

Address

6055 Lusk Boulevard, San Diego, CA, USA, 92121

Website

https://www.crinetics.com

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Executives

Richard Scott Struthers	director, officer: See Remarks	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Jeff E. Knight	officer: Chief Operating Officer	CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Dana Pizzuti	officer: Chief Development Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Marc Wilson	officer: See Remarks	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Stephen F. Betz	officer: Chief Scientific Officer	10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
James Hassard	officer: Chief Commercial Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Stephanie Okey	director	C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Alan Seth Krasner	officer: Chief Medical Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Vivaldi Coelho Rogerio	director	225 SECOND AVENUE, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Caren Deardorf	director	C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Ajay Madan	officer: Chief Development Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. 2, SAN DIEGO CA 92121
Camille L Bedrosian	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301